AI Drug Discovery for Pharma and Biotech

Drug discovery

147

papers

On emerging therapies

Overview

Cornelia de Lange syndrome (CdLS) is a multisystem genetic disorder caused by variants in cohesin complex genes (NIPBL, SMC1A, HDAC8, RAD21, SMC3). It features distinctive facial dysmorphism (synophrys, short nose, micrognathia), pre/postnatal growth restriction, limb anomalies, and intellectual disability. Common comorbidities include gastroesophageal reflux (60–75%), congenital heart defects (22–28%), hearing loss (75% conductive), and autism-spectrum behaviors [1][5][6][11][17].

Population

  • Estimated incidence: 1:10,000–30,000 live births, with underdiagnosis in mild cases [1][2][6][12].

Burden

  • High morbidity from recurrent pneumonia (secondary to reflux), volvulus risk, and progressive scoliosis [6][8][15].

  • Lifelong intellectual disability (74% moderate-severe) and communication challenges necessitate extensive support [4][6][11].

  • Caregiver strain due to self-injurious behaviors (38% prevalence) and complex care needs [4][13][18].

Therapies

  • Multidisciplinary care: Surgical correction (cleft palate, limb anomalies), antireflux medications/enteral feeding for GI issues, and physical/occupational therapy for motor deficits [3][5][8][18].

  • Behavioral interventions: Applied behavior analysis (ABA) and SSRIs for anxiety/aggression [13][18].

  • Surveillance: Regular audiology, ophthalmology, and cardiac evaluations [8][16].

Categories: rare abdominal surgical diseases, rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders, rare otorhinolaryngological diseases, rare surgical maxillo-facial diseases, rare surgical thoracic diseases

Research Papers

147 drug discovery papers about Cornelia de Lange syndrome. Recent publications:

147 drug discovery papers about Cornelia de Lange syndrome. Recent publications:

categories:

Small molecules

small molecules
2026-08-13 | Etiopathogenesis of Cornelia de Lange Syndrome: focusing on the effects of NIPBL mutation on neuronal differentiation

Cornelia de Lange Syndrome (CDLS) is a multisystem genetic disorder affecting children and it is characterized by growth retardation, distinctive facial features, limb malformations, intellectual disability and developmental impairment. CDLS is a cohesinopathy, since the pathogenic mutations are in genes encoding the cohesin complex, a key regulator of gene expression and chromatin organization, which are both impaired in CDLS patients. In the present study we considered a single CDLS patient characterized by a missense point mutation of the cohesin loader, NIPBL, which is mutated in 65% of CDLS cases. While loss of function and truncating mutations are associated with specific phenotypes and pathogenic mechanisms, the transcriptomic impact of missense mutations remains poorly understood. This study investigates the molecular mechanisms at the basis of the deficits of neuronal development observed in the CDLS case under study. To this purpose, induced pluripotent stem cells (iPSCs) were reprogrammed from the peripheral mononuclear blood cells of our CDLS patient (NIPBL mutation: c.5483G>A) and differentiated into cortical neurons. Samples collected at distinct stages of differentiation were assessed at the transcriptional and protein levels and they were compared with the healthy parents’ controls. Patient-derived early Neural-Progenitor-Cells (NPCs) exhibited a reduced capacity to differentiate and showed a limited expression of neuronal markers. These deficits were particularly evident at the late differentiation stages. Relative to healthy controls, CDLS cells showed an increased cell-size and an altered cell-cycle distribution (reduced S and G2/M and increased G0/G1 phases), suggesting a senescent-like phenotype. Transcriptomic analyses showed dysregulation of genes involved in multiple pathways, including WNT signaling and senescence-related pathways, which are often altered in CDLS models. Overall, the missense mutation under study impairs neuronal development and associates with up-regulation in the WNT signaling pathway, suggesting that WNT inhibitors are potential therapeutic agents.

Open article ↗



2026-06-01 | Neuropsychiatric Psychosis and Xanomeline in the treatment of an Adolescent with a MED13L mutation

Introduction The Mediator complex is a 26 gene multi-subunit transcriptional regulator essential for RNA polymerase II-mediated gene expression in humans. Mediator complex mutations cause Lujan and Cornelia de Lange syndrome. More specifically, MED13L mutations cause neurodevelopmental disorders with structural brain abnormalities, intellectual disability and autism. Reports of psychosis in MED13L variants are not common while treatment strategies are unmapped. Objectives A report is undertaken of the therapeutic potential of xanomeline to ameliorate psychotic symptoms in a treatment-resistant adolescent with a MED13L mutation. Methods Use of xanomeline is detailed in a 15-year-old male harboring a heterozygous de novo missense MED13L variant (c.3410 A>G, p.N1137S) and a 22q11.2 duplication copy number variant. Results A 15 year-old male with a MED13L deleterious point mutation presented with worsening of psychotic symptoms, and a diagnosis of schizoaffective disorder, bipolar type. Past psychiatric history was notable for prior hospitalizations in May and April 2024 for aggression, in December 2024 for aggression and suicidal ideation and in July 2025 for aggression. Prior trials include citalopram 10 mg (worsened agitation), aripiprazole 5 mg (ineffective), haloperidol 7.5 mg (ineffective), olanzapine 10 mg (ineffective), valproate 750 mg (tremors, weight gain), sertraline (worsening manic symptoms) in 2024 and Ativan 1 mg TID (disinhibition) in 2023. Given the poor response overall to various mood-stabilizing and antipsychotic medications, xanomeline at 50 mg (+ 20 mg trospium) twice daily, titrated to 100/20 mg twice daily was cross-tapered with risperidone. Over the next 2 weeks, the patient’s behavior improved, he was more social and no more aggressive episodes were evident. No significant side effects were noted from use of xanomeline. Conclusions Xanomeline-trospium is an antipsychotic recently approved by FDA in September 2024 for use in adults with schizophrenia. Xanomeline, a muscarinic M1/M4 agonist, is given in combination with trospium to minimize GI side effects. In our patient, the drug was well tolerated and produced positive effects on psychosis and aggression in a span of 2 weeks. Unlike most antipsychotic agents, xanomeline does not exert any effect on dopamine or serotonin receptors. Most common adverse reactions include GI symptoms such as nausea, dyspepsia. Genetic variants presenting with psychotic symptoms include the 22q11 microdeletion syndrome, Prader-Willi syndrome among others. Due to the organic brain dysfunction that these syndromes entail, psychotic syndromes can follow a torpid course with limited response to current treatment options. This report considers the use of the novel low-side effect profile xanomeline-trospium for the treatment of psychosis in genetic syndromes which can be more susceptible to side effects. Disclosure of Interest None Declared

Open article ↗



2026-05-01 | 1297 Breath-Holding Spell Triggered by CPAP in a 2-Year-Old Child with Cornelia de Lange Syndrome and Severe Obstructive Sleep Apnea

Abstract Introduction Breath-holding spells are benign paroxysmal events occurring in early childhood, most often triggered by emotional upset or painful stimuli. Continuous positive airway pressure (CPAP) therapy is commonly used in pediatric obstructive sleep apnea (OSA), though initiation may be stressful. To our knowledge, there are no prior reports of breath-holding spells associated with CPAP. Here, we describe what appears to be the first reported case of a cyanotic breath-holding spell occurring immediately after CPAP initiation in a 2-year-old child. Report of case(s) A 2-year-old boy with Cornelia de Lange syndrome and severe OSA (Obstructive apnea- hypopnea index of 65 events/hour) had sustained apnea and cyanosis immediately after CPAP initiation in the sleep lab. A rapid response was called and cardiopulmonary resuscitation was started, but patient quickly spontaneously recovered. The patient was subsequently admitted to the hospital for monitoring. CPAP was reattempted twice in the hospital and patient again had apnea with cyanosis and bradycardia. On the first attempt, recorded oxygen saturation decreased from 100% to 18% on CPAP and heart rate decreased from 143 to 70 beats per minute. On a repeat CPAP attempt after one hour, the patient again had apnea and oxygen saturation decreased to 66% and heart rate decreased from 180 to 51. The CPAP mask was removed and the patient spontaneously recovered both times. Given this CPAP intolerance, the patient was discharged home with oxygen at night for treatment of OSA. Overnight oximetry on 0.2 liter per minute of oxygen via nasal cannula showed an oxygen desaturation index of 11 events /hour and 6.1% of the night with an oxygen saturation below 90%. Conclusion Children with Cornelia de Lange syndrome and severe OSA are at a risk for breath – holding spells. CPAP initiation may trigger breath holding spells and sleep medicine clinicians should be aware of this to avoid unnecessary interventions. There is some evidence that behavioral interventions can lesson breath – holding spells in children with Cornelia de Lange syndrome, but treatments other than CPAP may be necessary in some cases. Support (if any)

Open article ↗



2026-03-30 | Combined inhalation anesthesia with sevoflurane and dexmedetomidine during oral cavity sanitation in a child with Cornelia de Lange syndrome

Cornelia de Lange syndrome is a rare hereditary orphan disease characterized by multiple dysembryogenetic stigmata, including musculoskeletal abnormalities, maxillofacial changes, neurologic disorders, and ocular involvement. A 13-year-old girl (body weight 54 kg, height 149 cm) was admitted to the dental clinic Stomatologiya NK (Nizhnekamsk) for oral cavity sanitation. The patient’s medical history included spastic tetraparesis, hydrocephalus with intracranial hypertension, and delayed psychomotor and speech development associated with Cornelia de Lange syndrome. No premedication was given before treatment. Anesthesia induction with sevoflurane was performed using a bolus technique. By the tenth breath, the child lost consciousness. The excitation stage occurred 45 s after the start of inhalation of the anesthetic gas mixture and lasted no more than 15 s. After peripheral venous catheterization, intravenous administration of 0.1% atropine sulfate (0.01 mg/kg), dexamethasone (0.1 mg/kg), and 1% propofol (2 mg/kg) was performed. Tracheal intubation was achieved on the second attempt using a guide (Mallampati class III; Cormack–Lehane grade 3), followed by initiation of pressure-controlled mechanical ventilation with transition to low-flow anesthesia: oxygen–air mixture 1 L/min and sevoflurane 2.5 vol% (minimum alveolar concentration, 1). During sevoflurane administration, continuous infusion of dexmedetomidine was maintained at 0.7 µg/(kg × h). After 20 minutes from the start of dexmedetomidine infusion, the sevoflurane dose was reduced to 1–1.2 vol% (minimum alveolar concentration, 0.4–0.5). During treatment, local infiltration anesthesia was not used. Fifteen minutes before the end of the procedure, paracetamol was administered intravenously at 15 mg/kg. Dexmedetomidine infusion was discontinued 15 min before completion of the dental treatment. Five minutes after discontinuation of sevoflurane, tracheal extubation was performed without complications, after which the patient was transferred to the recovery room. Muscle relaxants and opioid analgesics were not administered at any stage of anesthesia. Infusion therapy was not administered. Fifteen minutes after transfer to the recovery room, the consciousness score according to the Ramsay Sedation Scale was 2 points. One hour after completion of treatment, the patient was discharged home. The duration of anesthesia was 2 h 40 min, and that of the dental procedure was 2 h 30 min. This clinical case demonstrates the supra-additive effect of the combined use of sevoflurane and dexmedetomidine at subtherapeutic doses, providing adequate anesthesia at all stages of the dental intervention without local anesthesia. The case demonstrates the adequacy and sufficiency of the selected anesthesia technique, which may be further evaluated and validated in a larger patient cohort, including those with neurologic impairment.

Open article ↗



2026-03-29 | Lithium ameliorates neural differentiation restoring cell death balance in Cornelia de Lange syndrome 2D and 3D models.

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder that affects almost any organ, including the central nervous system. It leads to a wide range of neurodevelopmental delays, and there are currently no available clinical treatments. CdLS is caused by pathogenic variants in one of the 7 genes coding for the cohesin complex, a multimeric structure responsible for sister chromatid cohesion, or for cohesin ring-interacting proteins. Additionally, altered regulation of molecular pathways during development, including the canonical WNT pathway, can cause CdLS malformations. In our study, we evaluated the positive effects of using lithium as an activator of the canonical WNT pathway to ameliorate neural CdLS phenotype. We have exploited accurate two-dimensional (2D) and three-dimensional (3D) human central nervous system in vitro models representing disease-related neurobiological phenotypes: induced pluripotent stem cells of human origin (hiPSCs) differentiated into neural precursors, neurons, and brain organoids (BOs). CdLS models demonstrate alterations in proliferation and differentiation capabilities when mimicking HDAC8 haploinsufficiency. Furthermore, RNA-seq analysis of BOs revealed that both neuronal differentiation and the WNT pathway are downregulated when treated with the HDAC8 inhibitor alone. Following lithium treatment, cells show an enhanced ability to differentiate into the neuronal lineage. Additionally, our working hypothesis is that a specific mechanism may exist that, by connecting lipid metabolism, canonical WNT pathway, and cell death, results in typical CdLS neurodevelopmental deficits.

Open article ↗



proteins
2026-05-28 | Clinical delineation and genotype-phenotype correlation of 84 pediatric patients with Cornelia de Lange syndrome: insights from a single-center Chinese study.

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder, which has clinical and genetic heterogeneity. This study investigated the clinical and genetic characteristics of a large cohort of CdLS in China and elucidated genotype-phenotype correlations. The clinical manifestations, laboratory tests, and genetic testing of pediatric participants from January 2011 to December 2025 were retrospectively analyzed. We compared clinical phenotypes of patients with NIPBL variants versus those with variants in other causative genes, as well as among patients with different types of NIPBL variants. A total of 84 Chinese patients diagnosed with CdLS were included in this cohort. Growth curve analysis delineated distinct sex-specific patterns. Male patients experience severe growth faltering during puberty, suggesting an underlying deficit in sex hormone drive. This is further corroborated by the significant growth acceleration achieved with hormone replacement therapy in a male patient diagnosed with hypogonadotropic hypogonadism. NIPBL variants were the predominant cause, accounting for 66.7% of cases, and correlated with the most severe phenotypic spectrum. Notably, this subgroup exhibited significantly more severe growth retardation and a higher frequency of classic facial features (p < 0.001). Furthermore, severe upper limb deformities, such as oligodactyly, were identified exclusively in the NIPBL subgroup.Conclusion: This study characterized a Chinese CdLS cohort, establishing its first growth curves and observing a positive growth response to hormone therapy. Our findings confirm the link between NIPBL variants and the most severe phenotype, thereby underscoring the necessity of a genotype-stratified approach for clinical management and counseling.

Open article ↗



2025-07-23 | Two Years of Growth Hormone Therapy in a Child with Severe Short Stature Due to Overlap Syndrome with a Novel SETD5 Gene Mutation: Case Report and Review of the Literature

Background: SET domain-containing 5 (SETD5) is a member of the protein lysine-methyltransferase family. SETD5 gene mutations cause disorders of the epigenetic machinery which determinate phenotypic overlap characterized by several abnormalities. SEDT5 gene variants have been described in patients with KBG and Cornelia de Lange (CdL) syndromes. Case description: A female patient with severe short stature and intellectual disability had been followed since she was 9 years old. Several causes of short stature were ruled out. At the age of 12 years, her height was 114 cm (−5.22 SDS), weight 19 kg (−5.88 SDS), BMI 14.6 kg/m2 (−2.26 SDS), and was Tanner stage 1. The target height for the proband was 151.65 cm (−1.80 SDS). The bone age (BA) was delayed by 3 years compared to chronological age. The growth rate was persistently deficient (<<2 SDS). Physical examination revealed dysmorphic features. Genetic analysis documented a de novo SETD5 gene mutation (c.890_891delTT), responsible for phenotypes in the context of an overlap syndrome between the phenotype of MDR23, CdL and KBG syndromes. Recombinant growth hormone therapy (rhGH) was started at the age of 12 years. After both one year (+3.16 SDS) and two years (+2.9 SDS), the growth rate significantly increased compared with the pre-therapy period. Conclusion: This is the first case of a patient with overlap syndrome due to SETD5 mutation treated with rhGH. The review of the scientific literature highlighted the clinical and molecular features of SETD5 gene mutation and the use of rhGH therapy in patients suffering from CdL and KBG syndromes.

Open article ↗



2025-07-02 | Clinical and genetic characteristics of Cornelia de Lange syndrome in pediatric patients

ABSTRACT Importance Cornelia de Lange syndrome (CdLS) is a rare genetic disorder characterized by a spectrum of developmental and physical anomalies. Understanding the clinical and genetic landscape of CdLS in pediatric patients is crucial for improving diagnosis and management. Objective To investigate the clinical and genetic characteristics of 19 pediatric patients with CdLS in China, with a focus on identifying the association between genetic variants and clinical severity. Methods We performed whole exome sequencing on 19 patients with CdLS and compared their clinical characteristics based on the presence of null variants. Results Among the 19 patients, 16 (84.2%) showed global developmental delays and 14 (73.7%) experienced prenatal growth retardation and short stature. Craniofacial anomalies–short noses and anteverted nares were observed in 94.7% (18/19) of patients. Small hands and/or feet were present in 16 patients, skin manifestations (hirsutism or mottled skin) in six, and hearing loss in four. Genetic testing identified 19 variants in NIPBL (78.9%, 15/19), SMC1A (10.5%, 2/19), and RAD21 (10.5%, 2/19), including 13 novel variants. NIPBL null variants correlated significantly with more severe growth impairments ( P = 0.016) and microcephaly ( P = 0.004). Although complete protein function loss often correlated with more severe clinical presentations, no significant difference in clinical scoring was observed ( P = 0.600). Three patients treated with recombinant human growth hormone showed heterogeneous responses. Interpretation This study highlights the clinical heterogeneity of CdLS and suggests a potential link between specific genetic variants and disease severity. These findings warrant further research to optimize treatments and better understand the functional impact of these genetic variants.

Open article ↗



2017-06-07 | Successful Growth Hormone Therapy in Cornelia de Lange Syndrome

Cornelia de Lange syndrome (CdLS) is a both clinically and genetically heterogeneous syndrome. In its classical form, it is characterised by distinctive facial features, intra-uterine growth retardation, short stature, developmental delay, and anomalies in multiple organ systems. NIPBL, SMC1A, SMC3, RAD21 and HDAC8, all involved in the cohesin pathway, have been identified to cause CdLS. Growth hormone (GH) secretion has been reported as normal, and to our knowledge, there are no reports on the effect of recombinant human GH treatment in CdLS patients. We present a patient born small for gestational age with persistent severe growth retardation [height -3.4 standard deviation score (SDS)] and mild dysmorphic features, who was treated with GH from 4.3 years of age onward and was diagnosed 6 years later with CdLS using whole-exome sequencing. Treatment led to a height gain of 1.6 SDS over 8 years. Treatment was interrupted shortly due to high serum insulin-like growth factor-1 serum values. In conclusion, GH therapy may be effective and safe for short children with CdLS.

Open article ↗



2004-06-21 | Reduction of Pleural Effusion by OK-432 in a Fetus Complicated with Congenital Hydrothorax

A 29-year-old, primiparous woman was referred to our hospital at 21 weeks of gestation because of right pleural effusion in the fetus shown by routine ultrasonographic examination. Cytology revealed abundant lymphocytes, suggesting chylothorax. We removed the pleural effusion and injected OK-432 into the chest cavity at 24 and 25 weeks of gestation. Pleural effusion declined and an adhesion between the lung surface and the pleural membrane seemed to form. At 33 weeks of gestation, a female infant was born by cesarean section (1,090 g and Apgar score 6/8). Although she demonstrated slight retraction and tachypnea, management could be achieved by administration of oxygen alone without mechanical ventilation. Later, the baby was diagnosed as suffering from the Cornelia de Lange syndrome with characteristic features. OK-432 injections could thus prevent complications of chylothorax and hypoplastic lungs, without injury to either the baby or the mother.

Open article ↗



gene therapies
2026-08-02 | Exploring Upper Limb Malformation Associated With Cornelia De Lange Syndrome: A Clinical Case Report.

Upper extremity deformation may come in isolation, such as polydactyly, or be associated with a syndrome involving other body parts. Cornelia de Lange syndrome (CDLS) is a syndrome encompassing many abnormalities with some variation and a spectrum of severity. This case report presents a case of a baby with suspected CDLS. A 28-year-old woman, Gravida 3 Para 2, came to the polyclinic referred because of her small gestational age and a possibility of congenital abnormality. The ultrasound examination showed upper extremity malformation with hypoplasia of the left radius and ulna, right ulna, agenesis of the right ulna, intrauterine growth restriction, and polyhydramnios. An elective Caesarean section was performed at 37 weeks of gestational age due to two previous Caesarean sections. Baby girl was born at 1446 g, with a body length of 39 cm and an Apgar score of 6/8. The baby had some features of CDLS, such as thick eyebrows, a short nose, a concave nasal ridge, a long indistinct philtrum, and a distinct upper extremity malformation. CDLS was characterized by prenatal growth retardation, microcephaly, craniofacial abnormalities, hand or foot malformation, and hirsutism in the face. Prenatally, CDLS has some distinctive features in ultrasound, such as fetal growth retardation, craniofacial abnormalities, and limb malformation. CDLS has a broad spectrum of clinical presentation; its prognosis may vary based on the abnormality and the symptoms caused.

Open article ↗



2026-05-09 | Cohesin variants associated with human reproductive and developmental disorders.

The cohesin complex is an evolutionarily conserved multi-subunit protein assembly essential for sister chromatid cohesion, meiotic recombination, DNA double-strand break repair, and transcriptional regulation. Pathogenic variants in its subunits are implicated in a spectrum of reproductive and developmental disorders, including non-obstructive azoospermia, premature ovarian insufficiency, reproductive aging, aneuploidy, Cornelia de Lange syndrome, Roberts syndrome, cancer, and neuro-psychiatric disease. Consequently, identifying cohesin mutations is a priority for precision diagnostics and personalized medicine. This review systematically summarizes the cohesin variants linked to these pathologies, exploring their molecular mechanisms and clinical manifestations. A deeper understanding of these variants is crucial not only for deciphering disease etiology but also for guiding the development of targeted diagnostic strategies and therapeutic interventions, ultimately improving patient management and outcomes.

Open article ↗



2026-03-17 | Clinical and molecular findings in Cornelia de Lange syndrome. Case series.

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder caused by pathogenic variants in genes related to the regulation of cohesin transcription. It presents a very heterogeneous clinical phenotype, with wide variability in severity. To describe the clinical and molecular findings in patients diagnosed with CdLS. Observational and descriptive study conducted in patients with CdLS evaluated between April 1, 2020, and April 1, 2024, at the Clinical Genetics Unit, Pediatrics Service, of the Hospital Regional de Antofagasta. The diagnostic algorithm suggested by the first international consensus statement for CdLS was used, and the results of the genetic studies were analyzed. Six patients aged 0-17 years were included; 4 were male. Global developmental delay and/or intellectual disability, the presence of synophrys, abnormalities of the nose and lips, and hypertrichosis were confirmed in all patients. Heterozygous variants in the NIPBL gene were found in 5/6 patients (83.33%), all classified as pathogenic and associated with cases of classic CdLS. Four of the variants described in this study have not been previously reported in the literature. Neurological alterations, facial dysmorphism, and hypertrichosis were present in all patients studied. Heterozygous pathogenic variants in the NIPBL gene represented the main etio- pathogenic cause, allowing for timely family genetic counseling.

Open article ↗



2026-01-09 | Whole Exome Sequencing Uncovers Genetic Syndromes Associated with Orofacial Clefts presenting with Limb abnormalities in a Sub-Saharan African cohort.

Orofacial clefts (OFCs) are the most frequent congenital craniofacial anomalies that occur during embryonic development. The incidence is ~1 in 700 live births; it may occur in isolation or with other abnormalities, such as limb deformities. Congenital limb malformations are the second most prevalent birth defect, affecting 1 per 500 to 1000 live births. It can also occur in isolation or as part of a syndrome. This study investigated the genetic aetiology of OFCs co-occurring with limb abnormalities in a Sub-Saharan African cohort. Nine unrelated probands with concurrent OFC and limb anomalies were recruited, including one multiplex family involving an affected mother and proband. Whole exome sequencing (WES) was performed at 100X on the DNA samples obtained from affected families, utilising paired-end configuration on the Illumina HiSeq platform. Variant calling utilized the Sentieon workflow. Rare, deleterious variants were identified in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines on variant classification. De novo and other variants predicted as pathogenic were prioritized based on all possible Mendelian inheritance patterns, including variable penetrance and expressivity. Pathway enrichment analysis, protein-protein interactions, and gene expression analysis were undertaken to decipher the biological functions of implicated genes. All cases were syndromic, presenting with preaxial and postaxial limb anomalies along with other craniofacial features. WES revealed plausible pathogenic variants in pleiotropic genes (TP63, NIPBL, MYH3, FGFR2) in four simplex cases. In four other simplex probands, multiple rare variants were identified in developmentally relevant genes (e.g., RGPD5, FAM90A26, FOXD4L1, FAM170A, DLG1, ANKRD1, TRIM74, TRIM73, PRDM9) necessary for normal craniofacial and limb development. The multiplex family had two affected individuals (the mother and the proband), both carrying a TP63 variant, consistent with autosomal dominant inheritance with variable expressivity. Most of the observed variants were de novo, with some being novel. While some cases can be attributed to single-gene syndromes (e.g., NIPBL-associated Cornelia de Lange Syndrome), others may result from multiple co-occurring syndromes. These findings will inform recurrence risk estimates, genetic counselling, and clinical management.

Open article ↗



2025-12-15 | A Review on Cornelia De Lange Syndrome

Cornelia de Lange Syndrome (CdLS) is a rare genetic condition that affects multiple body systems. It is marked by distinctive facial features, delayed growth, limb differences, and a wide range of cognitive and behavioral challenges. First identified in 1933 by Dutch pediatrician Cornelia de Lange, the syndrome occurs in roughly 1 in 10,000 to 30,000 live births. The severity of CdLS varies widely, from classic, clearly recognizable cases to milder or atypical forms with subtler features. The disorder is mainly caused by mutations in genes related to the cohesin complex—such as NIPBL, SMC1A, SMC3, RAD21, HDAC8, BRD4, ANKRD11, and MAU2—which disrupt gene regulation, DNA repair, and oxidative stress responses, though basic sister chromatid cohesion is usually intact. Individuals with CdLS may display a combination of facial and limb abnormalities, growth restriction, intellectual disability, behavioral difficulties, and problems involving organs such as the heart, digestive system, kidneys, eyes, and reproductive organs. Mosaicism is relatively common and can influence the severity and variability of symptoms, sometimes making diagnosis more challenging. Genetic testing through targeted gene panels or exome sequencing is key for diagnosis, with careful selection of tissue samples to detect mosaic variants. Prenatal diagnosis is possible in families at risk or when ultrasound findings raise suspicion, but interpretation can be complex. Managing CdLS requires a multidisciplinary approach, including nutritional support, surgical interventions, medications for seizures or behavioral concerns, and ongoing therapies such as physical, occupational, and speech therapy. Despite advances in genomic research, some cases remain unexplained, underscoring the complexity of this condition.

Open article ↗



oligonucleotides
2023-04-01 | Genetic and Genomic Analyses of Drosophila melanogaster Models of Chromatin Modification Disorders.

Switch/Sucrose Non-Fermentable (SWI/SNF)-related intellectual disability disorders (SSRIDDs) and Cornelia de Lange syndrome are rare syndromic neurodevelopmental disorders with overlapping clinical phenotypes. SSRIDDs are associated with the BAF (Brahma-Related Gene-1 Associated Factor) complex, whereas CdLS is a disorder of chromatin modification associated with the cohesin complex. Here, we used RNA interference in Drosophila melanogaster to reduce expression of six genes (brm, osa, Snr1, SMC1, SMC3, vtd) orthologous to human genes associated with SSRIDDs and CdLS. These fly models exhibit changes in sleep, activity, startle behavior (a proxy for sensorimotor integration) and brain morphology. Whole genome RNA sequencing identified 9,657 differentially expressed genes (FDR < 0.05), 156 of which are differentially expressed in both sexes in SSRIDD- and CdLS-specific analyses, including Bap60, which is orthologous to SMARCD1, a SSRIDD-associated BAF component, k-means clustering reveals genes co-regulated within and across SSRIDD and CdLS fly models. RNAi-mediated reduction of expression of six genes co-regulated with focal genes brm, osa, and/or Snr1 recapitulated changes in behavior of the focal genes. Based on the assumption that fundamental biological processes are evolutionarily conserved, Drosophila models can be used to understand underlying molecular effects of variants in chromatin-modification pathways and may aid in discovery of drugs that ameliorate deleterious phenotypic effects.

Open article ↗



2021-06-08 | Neuropsychiatric Functioning in CDLS: A Detailed Phenotype and Genotype Correlation

Abstract Background : Cornelia de Lange Syndrome (CdLS) is a rare genetic disorder and its phenotype clinical expression is widely variable. Despite the growing interest on genotype-phenotype correlations and on behaviour phenotype of genetic syndromes, specific studies in CdLS cohorts evaluating the correlations between genotype and neurodevelopmental characteristics, Behaviour and communicative aspects are limited, most of these studies are descriptive and there is a lack of specific assessment protocols. Methods : Neurodevelopmental and Behavioural phenotype of all the patients (N = 38) was assessed using a specific neuropsychiatric protocol, concerning Intellectual Quotient (IQ), General Quotient of Development (GQ), communicative skills, behavioural aspects and adaptive behaviour based on direct and indirect evaluation. Subsequently, we searched for possible genotype–phenotype correlations comparing individuals with NIPBL variants (CdLS NIPBL mutated group) and patients with negative molecular results (CdLS clinical diagnosis group). Results : The first part of the study showed a higher percentage of subjects with normal Intellectual Quotient (IQ) and Borderline Intellectual Functioning if compared with previous data; adaptive skills were lower than expected for age in all participants and the weakest areas were Socialization, Motor Skills, and Communication. Expressive language was more compromised than receptive language, nevertheless receptive abilities were also impaired. 39.5% of the sample presented with Autism Spectrum Disorder (ASD). By stratifying CdLS phenotypes by genetic, NIPBL mutated individuals demonstrated a worse trend in cognitive functioning, in communication expressive skills, in motor skills and in ASD symptoms in comparison with the Clinical Diagnosis Group. Individuals with non-Truncating mutation (mostly missense) displayed better abilities in Communication and in relational aspects with no ASD while Truncating individuals presented with worse abilities in Daily Living Skills, Socialization, Motor Skills, and Communicative abilities. Conclusions : These findings should increase our awareness of the strengths and weaknesses points in CdLS individuals to guide appropriate targeted management; interventions addressing communicative impairments represent a clinical priority in CdLS patients.

Open article ↗



2017-12-20 | Regulation of the cohesin-loading factor NIPBL: Role of the lncRNA NIPBL-AS1 and identification of a distal enhancer element

Cohesin is crucial for genome stability, cell division, transcription and chromatin organization. Its functions critically depend on NIPBL, the cohesin-loader protein that is found to be mutated in >60% of the cases of Cornelia de Lange syndrome (CdLS). Other mutations are described in the cohesin subunits SMC1A, RAD21, SMC3 and the HDAC8 protein. In 25–30% of CdLS cases no mutation in the known CdLS genes is detected. Until now, functional elements in the noncoding genome were not characterized in the molecular etiology of CdLS and therefore are excluded from mutation screening, although the impact of such mutations has now been recognized for a wide range of diseases. We have identified different elements of the noncoding genome involved in regulation of the NIPBL gene. NIPBL-AS1 is a long non-coding RNA transcribed upstream and antisense to NIPBL. By knockdown and transcription blocking experiments, we could show that not the NIPBL-AS1 gene product, but its actual transcription is important to regulate NIPBL expression levels. This reveals a possibility to boost the transcriptional activity of the NIPBL gene by interfering with the NIPBL-AS1 lncRNA. Further, we have identified a novel distal enhancer regulating both NIPBL and NIPBL-AS1. Deletion of the enhancer using CRISPR genome editing in HEK293T cells reduces expression of NIPBL, NIPBL-AS1 as well as genes found to be dysregulated in CdLS.

Open article ↗



2017-09-12 | Decreased cohesin in the brain leads to defective synapse development and anxiety-related behavior.

Abnormal epigenetic regulation can cause the nervous system to develop abnormally. Here, we sought to understand the mechanism by which this occurs by investigating the protein complex cohesin, which is considered to regulate gene expression and, when defective, is associated with higher-level brain dysfunction and the developmental disorder Cornelia de Lange syndrome (CdLS). We generated conditional Smc3-knockout mice and observed greater dendritic complexity and larger numbers of immature synapses in the cerebral cortex of Smc3+/- mice. Smc3+/- mice also exhibited more anxiety-related behavior, which is a symptom of CdLS. Further, a gene ontology analysis after RNA-sequencing suggested the enrichment of immune processes, particularly the response to interferons, in the Smc3+/- mice. Indeed, fewer synapses formed in their cortical neurons, and this phenotype was rescued by STAT1 knockdown. Thus, low levels of cohesin expression in the developing brain lead to changes in gene expression that in turn lead to a specific and abnormal neuronal and behavioral phenotype.

Open article ↗



2015-11-25 | Esco2 regulates cx43 expression during skeletal regeneration in the zebrafish fin.

Background: Roberts syndrome (RBS) is a rare genetic disorder characterized by craniofacial abnormalities, limb malformation, and often severe mental retardation. RBS arises from mutations in ESCO2 that encodes an acetyltransferase and modifies the cohesin subunit SMC3. Mutations in SCC2/NIPBL (encodes a cohesin loader), SMC3 or other cohesin genes ( SMC1, RAD21/MCD1 ) give rise to a related developmental malady termed Cornelia de Lange syndrome (CdLS). RBS and CdLS exhibit overlapping phenotypes, but RBS is thought to arise through mitotic failure and limited progenitor cell proliferation while CdLS arises through transcriptional dysregulation. Here, we use the zebrafish regenerating fin model to test the mechanism through which RBS‐type phenotypes arise. Results : esco2 is up‐regulated during fin regeneration and specifically within the blastema. esco2 knockdown adversely affects both tissue and bone growth in regenerating fins—consistent with a role in skeletal morphogenesis. esco2 ‐knockdown significantly diminishes cx43/gja1 expression which encodes the gap junction connexin subunit required for cell–cell communication. cx43 mutations cause the short fin ( sof b123 ) phenotype in zebrafish and oculodentodigital dysplasia (ODDD) in humans. Importantly, miR‐133‐dependent cx43 overexpression rescues esco2 ‐dependent growth defects. Conclusions : These results conceptually link ODDD to cohesinopathies and provide evidence that ESCO2 may play a transcriptional role critical for human development. Developmental Dynamics 245:7–21, 2016 . © 2015 Wiley Periodicals, Inc.

Open article ↗



other
2026-05-13 | Idiopathic retinal vasculitis with neovascularisation in Cornelia de Lange syndrome associated with a novel HDAC8 variant.

To describe a case of unilateral idiopathic retinal vasculitis with neovascularisation in a patient with Cornelia de Lange syndrome (CdLS) and to expand the known ophthalmic phenotype of this condition. Observational case report of an 18-year-old girl with clinically diagnosed CdLS associated with a novel HDAC8 variant. Multimodal retinal imaging, including fundus photography, fluorescein angiography, and optical coherence tomography, was performed. Infectious and autoimmune causes were systematically investigated and excluded. The patient developed unilateral retinal vasculitis with macular edema and neovascularisation. Imaging confirmed vascular leakage, retinal ischemia, and macular involvement in the affected eye. Treatment with intravitreal aflibercept and panretinal photocoagulation led to regression of neovascularisation; however, recurrent macular edema was observed during follow-up. This case represents the first report of inflammatory retinal disease in CdLS. It broadens the spectrum of ocular manifestations associated with the disorder and emphasizes the importance of early and thorough retinal assessment in these patients.

Open article ↗



2025-04-25 | Recurrent Sinopulmonary Infections in an 8-Year-Old Boy with Cornelia de Lange Syndrome

Introduction Cornelia de Lange syndrome (CdLS) is a rare genetic disorder with an estimated prevalence of 1 in 10,000 live births worldwide. It presents with a spectrum of severity, ranging from mild to severe marked by characteristic facial features, growth delay, intellectual disability, heart defects, gastrointestinal issues, hearing loss, myopia, and frequent upper and lower respiratory infections. The majority of genetic variants found in CdLS are associated with variants in the NIPBL gene, which encodes a regulatory protein crucial for the function of the cohesin complex. Case Description We present an 8-year-old male with a history of dysmorphic facial features, global developmental delay, aortic coarctation, lagophthalmos, hearing loss, and recurrent upper and lower sinopulmonary infections. There is no family history of immunodeficiencies or other genetic syndromes and patients born outside the United States. Commercial whole-exome sequencing performed at 7 years of age revealed a heterozygous de novo pathogenic variant in NIPBL (c.8257 C&gt;G, p.R2753G). Complete blood count with differential, basic lymphocyte subsets, and immunoglobulins were within normal limits. Patient was immune to varicella, hepatitis B, tetanus, and diphtheria post-vaccination but only had 1/23 strep pneumoniae titers above 1.3 ug/mL and only 4/23 above 0.5 ug/mL after primary Prevnar 13 series. Advanced phenotyping showed increased percentage of transitional B cells, increased proportion of CD8+ TEMRA cells, reverse CD4/CD8 ratio at 0.69, and normal mitogen-induced lymphocyte proliferation to PHA and ConA with PWM at 50% below the lower limit of normal. Patient given booster vaccination with Pneumovax and had improvement in strep pneumoniae titers to 16/23 protective above 1.3 ug/mL and decreased clinical infections. Discussion The cohesin protein complex plays a significant role in the immune system, and altered expression of immune-related genes in patients with CdLS may explain the varying degrees of immunodeficiency observed in these individuals. Although no specific immune defect has been universally identified in CdLS, and there are no established guidelines for managing immune issues or vaccination in this population, it is important to conduct clinical immunologic evaluations for CdLS patients who experience recurrent infections as booster vaccinations can significantly improve these patients’ quality of life.

Open article ↗



2023-11-02 | Coats' Disease in a Patient With Cornelia de Lange Syndrome: Management With Laser and Bevacizumab.

Cornelia de Lange syndrome is a congenital disorder with multisystem abnormalities including multiple ocular findings. The authors report a case of Coats' disease in a patient with Cornelia de Lange syndrome who was successfully treated with laser and intravitreal bevacizumab. This case demonstrates the importance of fluorescein angiography in making the diagnosis and directing treatment and the efficacy of combined laser with intravitreal anti-vascular endothelial growth factor therapy for persistent vascular leakage associated with Coats' disease in Cornelia de Lange syndrome. [J Pediatr Ophthalmol Strabismus. 2023;60(4):e45-e48.].

Open article ↗



2020-04-19 | Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic.

Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.

Open article ↗



small molecules
2026-08-13 | Etiopathogenesis of Cornelia de Lange Syndrome: focusing on the effects of NIPBL mutation on neuronal differentiation

Cornelia de Lange Syndrome (CDLS) is a multisystem genetic disorder affecting children and it is characterized by growth retardation, distinctive facial features, limb malformations, intellectual disability and developmental impairment. CDLS is a cohesinopathy, since the pathogenic mutations are in genes encoding the cohesin complex, a key regulator of gene expression and chromatin organization, which are both impaired in CDLS patients. In the present study we considered a single CDLS patient characterized by a missense point mutation of the cohesin loader, NIPBL, which is mutated in 65% of CDLS cases. While loss of function and truncating mutations are associated with specific phenotypes and pathogenic mechanisms, the transcriptomic impact of missense mutations remains poorly understood. This study investigates the molecular mechanisms at the basis of the deficits of neuronal development observed in the CDLS case under study. To this purpose, induced pluripotent stem cells (iPSCs) were reprogrammed from the peripheral mononuclear blood cells of our CDLS patient (NIPBL mutation: c.5483G>A) and differentiated into cortical neurons. Samples collected at distinct stages of differentiation were assessed at the transcriptional and protein levels and they were compared with the healthy parents’ controls. Patient-derived early Neural-Progenitor-Cells (NPCs) exhibited a reduced capacity to differentiate and showed a limited expression of neuronal markers. These deficits were particularly evident at the late differentiation stages. Relative to healthy controls, CDLS cells showed an increased cell-size and an altered cell-cycle distribution (reduced S and G2/M and increased G0/G1 phases), suggesting a senescent-like phenotype. Transcriptomic analyses showed dysregulation of genes involved in multiple pathways, including WNT signaling and senescence-related pathways, which are often altered in CDLS models. Overall, the missense mutation under study impairs neuronal development and associates with up-regulation in the WNT signaling pathway, suggesting that WNT inhibitors are potential therapeutic agents.

Open article ↗



2026-06-01 | Neuropsychiatric Psychosis and Xanomeline in the treatment of an Adolescent with a MED13L mutation

Introduction The Mediator complex is a 26 gene multi-subunit transcriptional regulator essential for RNA polymerase II-mediated gene expression in humans. Mediator complex mutations cause Lujan and Cornelia de Lange syndrome. More specifically, MED13L mutations cause neurodevelopmental disorders with structural brain abnormalities, intellectual disability and autism. Reports of psychosis in MED13L variants are not common while treatment strategies are unmapped. Objectives A report is undertaken of the therapeutic potential of xanomeline to ameliorate psychotic symptoms in a treatment-resistant adolescent with a MED13L mutation. Methods Use of xanomeline is detailed in a 15-year-old male harboring a heterozygous de novo missense MED13L variant (c.3410 A>G, p.N1137S) and a 22q11.2 duplication copy number variant. Results A 15 year-old male with a MED13L deleterious point mutation presented with worsening of psychotic symptoms, and a diagnosis of schizoaffective disorder, bipolar type. Past psychiatric history was notable for prior hospitalizations in May and April 2024 for aggression, in December 2024 for aggression and suicidal ideation and in July 2025 for aggression. Prior trials include citalopram 10 mg (worsened agitation), aripiprazole 5 mg (ineffective), haloperidol 7.5 mg (ineffective), olanzapine 10 mg (ineffective), valproate 750 mg (tremors, weight gain), sertraline (worsening manic symptoms) in 2024 and Ativan 1 mg TID (disinhibition) in 2023. Given the poor response overall to various mood-stabilizing and antipsychotic medications, xanomeline at 50 mg (+ 20 mg trospium) twice daily, titrated to 100/20 mg twice daily was cross-tapered with risperidone. Over the next 2 weeks, the patient’s behavior improved, he was more social and no more aggressive episodes were evident. No significant side effects were noted from use of xanomeline. Conclusions Xanomeline-trospium is an antipsychotic recently approved by FDA in September 2024 for use in adults with schizophrenia. Xanomeline, a muscarinic M1/M4 agonist, is given in combination with trospium to minimize GI side effects. In our patient, the drug was well tolerated and produced positive effects on psychosis and aggression in a span of 2 weeks. Unlike most antipsychotic agents, xanomeline does not exert any effect on dopamine or serotonin receptors. Most common adverse reactions include GI symptoms such as nausea, dyspepsia. Genetic variants presenting with psychotic symptoms include the 22q11 microdeletion syndrome, Prader-Willi syndrome among others. Due to the organic brain dysfunction that these syndromes entail, psychotic syndromes can follow a torpid course with limited response to current treatment options. This report considers the use of the novel low-side effect profile xanomeline-trospium for the treatment of psychosis in genetic syndromes which can be more susceptible to side effects. Disclosure of Interest None Declared

Open article ↗



2026-05-01 | 1297 Breath-Holding Spell Triggered by CPAP in a 2-Year-Old Child with Cornelia de Lange Syndrome and Severe Obstructive Sleep Apnea

Abstract Introduction Breath-holding spells are benign paroxysmal events occurring in early childhood, most often triggered by emotional upset or painful stimuli. Continuous positive airway pressure (CPAP) therapy is commonly used in pediatric obstructive sleep apnea (OSA), though initiation may be stressful. To our knowledge, there are no prior reports of breath-holding spells associated with CPAP. Here, we describe what appears to be the first reported case of a cyanotic breath-holding spell occurring immediately after CPAP initiation in a 2-year-old child. Report of case(s) A 2-year-old boy with Cornelia de Lange syndrome and severe OSA (Obstructive apnea- hypopnea index of 65 events/hour) had sustained apnea and cyanosis immediately after CPAP initiation in the sleep lab. A rapid response was called and cardiopulmonary resuscitation was started, but patient quickly spontaneously recovered. The patient was subsequently admitted to the hospital for monitoring. CPAP was reattempted twice in the hospital and patient again had apnea with cyanosis and bradycardia. On the first attempt, recorded oxygen saturation decreased from 100% to 18% on CPAP and heart rate decreased from 143 to 70 beats per minute. On a repeat CPAP attempt after one hour, the patient again had apnea and oxygen saturation decreased to 66% and heart rate decreased from 180 to 51. The CPAP mask was removed and the patient spontaneously recovered both times. Given this CPAP intolerance, the patient was discharged home with oxygen at night for treatment of OSA. Overnight oximetry on 0.2 liter per minute of oxygen via nasal cannula showed an oxygen desaturation index of 11 events /hour and 6.1% of the night with an oxygen saturation below 90%. Conclusion Children with Cornelia de Lange syndrome and severe OSA are at a risk for breath – holding spells. CPAP initiation may trigger breath holding spells and sleep medicine clinicians should be aware of this to avoid unnecessary interventions. There is some evidence that behavioral interventions can lesson breath – holding spells in children with Cornelia de Lange syndrome, but treatments other than CPAP may be necessary in some cases. Support (if any)

Open article ↗



2026-03-30 | Combined inhalation anesthesia with sevoflurane and dexmedetomidine during oral cavity sanitation in a child with Cornelia de Lange syndrome

Cornelia de Lange syndrome is a rare hereditary orphan disease characterized by multiple dysembryogenetic stigmata, including musculoskeletal abnormalities, maxillofacial changes, neurologic disorders, and ocular involvement. A 13-year-old girl (body weight 54 kg, height 149 cm) was admitted to the dental clinic Stomatologiya NK (Nizhnekamsk) for oral cavity sanitation. The patient’s medical history included spastic tetraparesis, hydrocephalus with intracranial hypertension, and delayed psychomotor and speech development associated with Cornelia de Lange syndrome. No premedication was given before treatment. Anesthesia induction with sevoflurane was performed using a bolus technique. By the tenth breath, the child lost consciousness. The excitation stage occurred 45 s after the start of inhalation of the anesthetic gas mixture and lasted no more than 15 s. After peripheral venous catheterization, intravenous administration of 0.1% atropine sulfate (0.01 mg/kg), dexamethasone (0.1 mg/kg), and 1% propofol (2 mg/kg) was performed. Tracheal intubation was achieved on the second attempt using a guide (Mallampati class III; Cormack–Lehane grade 3), followed by initiation of pressure-controlled mechanical ventilation with transition to low-flow anesthesia: oxygen–air mixture 1 L/min and sevoflurane 2.5 vol% (minimum alveolar concentration, 1). During sevoflurane administration, continuous infusion of dexmedetomidine was maintained at 0.7 µg/(kg × h). After 20 minutes from the start of dexmedetomidine infusion, the sevoflurane dose was reduced to 1–1.2 vol% (minimum alveolar concentration, 0.4–0.5). During treatment, local infiltration anesthesia was not used. Fifteen minutes before the end of the procedure, paracetamol was administered intravenously at 15 mg/kg. Dexmedetomidine infusion was discontinued 15 min before completion of the dental treatment. Five minutes after discontinuation of sevoflurane, tracheal extubation was performed without complications, after which the patient was transferred to the recovery room. Muscle relaxants and opioid analgesics were not administered at any stage of anesthesia. Infusion therapy was not administered. Fifteen minutes after transfer to the recovery room, the consciousness score according to the Ramsay Sedation Scale was 2 points. One hour after completion of treatment, the patient was discharged home. The duration of anesthesia was 2 h 40 min, and that of the dental procedure was 2 h 30 min. This clinical case demonstrates the supra-additive effect of the combined use of sevoflurane and dexmedetomidine at subtherapeutic doses, providing adequate anesthesia at all stages of the dental intervention without local anesthesia. The case demonstrates the adequacy and sufficiency of the selected anesthesia technique, which may be further evaluated and validated in a larger patient cohort, including those with neurologic impairment.

Open article ↗



2026-03-29 | Lithium ameliorates neural differentiation restoring cell death balance in Cornelia de Lange syndrome 2D and 3D models.

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder that affects almost any organ, including the central nervous system. It leads to a wide range of neurodevelopmental delays, and there are currently no available clinical treatments. CdLS is caused by pathogenic variants in one of the 7 genes coding for the cohesin complex, a multimeric structure responsible for sister chromatid cohesion, or for cohesin ring-interacting proteins. Additionally, altered regulation of molecular pathways during development, including the canonical WNT pathway, can cause CdLS malformations. In our study, we evaluated the positive effects of using lithium as an activator of the canonical WNT pathway to ameliorate neural CdLS phenotype. We have exploited accurate two-dimensional (2D) and three-dimensional (3D) human central nervous system in vitro models representing disease-related neurobiological phenotypes: induced pluripotent stem cells of human origin (hiPSCs) differentiated into neural precursors, neurons, and brain organoids (BOs). CdLS models demonstrate alterations in proliferation and differentiation capabilities when mimicking HDAC8 haploinsufficiency. Furthermore, RNA-seq analysis of BOs revealed that both neuronal differentiation and the WNT pathway are downregulated when treated with the HDAC8 inhibitor alone. Following lithium treatment, cells show an enhanced ability to differentiate into the neuronal lineage. Additionally, our working hypothesis is that a specific mechanism may exist that, by connecting lipid metabolism, canonical WNT pathway, and cell death, results in typical CdLS neurodevelopmental deficits.

Open article ↗



proteins
2026-05-28 | Clinical delineation and genotype-phenotype correlation of 84 pediatric patients with Cornelia de Lange syndrome: insights from a single-center Chinese study.

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder, which has clinical and genetic heterogeneity. This study investigated the clinical and genetic characteristics of a large cohort of CdLS in China and elucidated genotype-phenotype correlations. The clinical manifestations, laboratory tests, and genetic testing of pediatric participants from January 2011 to December 2025 were retrospectively analyzed. We compared clinical phenotypes of patients with NIPBL variants versus those with variants in other causative genes, as well as among patients with different types of NIPBL variants. A total of 84 Chinese patients diagnosed with CdLS were included in this cohort. Growth curve analysis delineated distinct sex-specific patterns. Male patients experience severe growth faltering during puberty, suggesting an underlying deficit in sex hormone drive. This is further corroborated by the significant growth acceleration achieved with hormone replacement therapy in a male patient diagnosed with hypogonadotropic hypogonadism. NIPBL variants were the predominant cause, accounting for 66.7% of cases, and correlated with the most severe phenotypic spectrum. Notably, this subgroup exhibited significantly more severe growth retardation and a higher frequency of classic facial features (p < 0.001). Furthermore, severe upper limb deformities, such as oligodactyly, were identified exclusively in the NIPBL subgroup.Conclusion: This study characterized a Chinese CdLS cohort, establishing its first growth curves and observing a positive growth response to hormone therapy. Our findings confirm the link between NIPBL variants and the most severe phenotype, thereby underscoring the necessity of a genotype-stratified approach for clinical management and counseling.

Open article ↗



2025-07-23 | Two Years of Growth Hormone Therapy in a Child with Severe Short Stature Due to Overlap Syndrome with a Novel SETD5 Gene Mutation: Case Report and Review of the Literature

Background: SET domain-containing 5 (SETD5) is a member of the protein lysine-methyltransferase family. SETD5 gene mutations cause disorders of the epigenetic machinery which determinate phenotypic overlap characterized by several abnormalities. SEDT5 gene variants have been described in patients with KBG and Cornelia de Lange (CdL) syndromes. Case description: A female patient with severe short stature and intellectual disability had been followed since she was 9 years old. Several causes of short stature were ruled out. At the age of 12 years, her height was 114 cm (−5.22 SDS), weight 19 kg (−5.88 SDS), BMI 14.6 kg/m2 (−2.26 SDS), and was Tanner stage 1. The target height for the proband was 151.65 cm (−1.80 SDS). The bone age (BA) was delayed by 3 years compared to chronological age. The growth rate was persistently deficient (<<2 SDS). Physical examination revealed dysmorphic features. Genetic analysis documented a de novo SETD5 gene mutation (c.890_891delTT), responsible for phenotypes in the context of an overlap syndrome between the phenotype of MDR23, CdL and KBG syndromes. Recombinant growth hormone therapy (rhGH) was started at the age of 12 years. After both one year (+3.16 SDS) and two years (+2.9 SDS), the growth rate significantly increased compared with the pre-therapy period. Conclusion: This is the first case of a patient with overlap syndrome due to SETD5 mutation treated with rhGH. The review of the scientific literature highlighted the clinical and molecular features of SETD5 gene mutation and the use of rhGH therapy in patients suffering from CdL and KBG syndromes.

Open article ↗



2025-07-02 | Clinical and genetic characteristics of Cornelia de Lange syndrome in pediatric patients

ABSTRACT Importance Cornelia de Lange syndrome (CdLS) is a rare genetic disorder characterized by a spectrum of developmental and physical anomalies. Understanding the clinical and genetic landscape of CdLS in pediatric patients is crucial for improving diagnosis and management. Objective To investigate the clinical and genetic characteristics of 19 pediatric patients with CdLS in China, with a focus on identifying the association between genetic variants and clinical severity. Methods We performed whole exome sequencing on 19 patients with CdLS and compared their clinical characteristics based on the presence of null variants. Results Among the 19 patients, 16 (84.2%) showed global developmental delays and 14 (73.7%) experienced prenatal growth retardation and short stature. Craniofacial anomalies–short noses and anteverted nares were observed in 94.7% (18/19) of patients. Small hands and/or feet were present in 16 patients, skin manifestations (hirsutism or mottled skin) in six, and hearing loss in four. Genetic testing identified 19 variants in NIPBL (78.9%, 15/19), SMC1A (10.5%, 2/19), and RAD21 (10.5%, 2/19), including 13 novel variants. NIPBL null variants correlated significantly with more severe growth impairments ( P = 0.016) and microcephaly ( P = 0.004). Although complete protein function loss often correlated with more severe clinical presentations, no significant difference in clinical scoring was observed ( P = 0.600). Three patients treated with recombinant human growth hormone showed heterogeneous responses. Interpretation This study highlights the clinical heterogeneity of CdLS and suggests a potential link between specific genetic variants and disease severity. These findings warrant further research to optimize treatments and better understand the functional impact of these genetic variants.

Open article ↗



2017-06-07 | Successful Growth Hormone Therapy in Cornelia de Lange Syndrome

Cornelia de Lange syndrome (CdLS) is a both clinically and genetically heterogeneous syndrome. In its classical form, it is characterised by distinctive facial features, intra-uterine growth retardation, short stature, developmental delay, and anomalies in multiple organ systems. NIPBL, SMC1A, SMC3, RAD21 and HDAC8, all involved in the cohesin pathway, have been identified to cause CdLS. Growth hormone (GH) secretion has been reported as normal, and to our knowledge, there are no reports on the effect of recombinant human GH treatment in CdLS patients. We present a patient born small for gestational age with persistent severe growth retardation [height -3.4 standard deviation score (SDS)] and mild dysmorphic features, who was treated with GH from 4.3 years of age onward and was diagnosed 6 years later with CdLS using whole-exome sequencing. Treatment led to a height gain of 1.6 SDS over 8 years. Treatment was interrupted shortly due to high serum insulin-like growth factor-1 serum values. In conclusion, GH therapy may be effective and safe for short children with CdLS.

Open article ↗



2004-06-21 | Reduction of Pleural Effusion by OK-432 in a Fetus Complicated with Congenital Hydrothorax

A 29-year-old, primiparous woman was referred to our hospital at 21 weeks of gestation because of right pleural effusion in the fetus shown by routine ultrasonographic examination. Cytology revealed abundant lymphocytes, suggesting chylothorax. We removed the pleural effusion and injected OK-432 into the chest cavity at 24 and 25 weeks of gestation. Pleural effusion declined and an adhesion between the lung surface and the pleural membrane seemed to form. At 33 weeks of gestation, a female infant was born by cesarean section (1,090 g and Apgar score 6/8). Although she demonstrated slight retraction and tachypnea, management could be achieved by administration of oxygen alone without mechanical ventilation. Later, the baby was diagnosed as suffering from the Cornelia de Lange syndrome with characteristic features. OK-432 injections could thus prevent complications of chylothorax and hypoplastic lungs, without injury to either the baby or the mother.

Open article ↗



gene therapies
2026-08-02 | Exploring Upper Limb Malformation Associated With Cornelia De Lange Syndrome: A Clinical Case Report.

Upper extremity deformation may come in isolation, such as polydactyly, or be associated with a syndrome involving other body parts. Cornelia de Lange syndrome (CDLS) is a syndrome encompassing many abnormalities with some variation and a spectrum of severity. This case report presents a case of a baby with suspected CDLS. A 28-year-old woman, Gravida 3 Para 2, came to the polyclinic referred because of her small gestational age and a possibility of congenital abnormality. The ultrasound examination showed upper extremity malformation with hypoplasia of the left radius and ulna, right ulna, agenesis of the right ulna, intrauterine growth restriction, and polyhydramnios. An elective Caesarean section was performed at 37 weeks of gestational age due to two previous Caesarean sections. Baby girl was born at 1446 g, with a body length of 39 cm and an Apgar score of 6/8. The baby had some features of CDLS, such as thick eyebrows, a short nose, a concave nasal ridge, a long indistinct philtrum, and a distinct upper extremity malformation. CDLS was characterized by prenatal growth retardation, microcephaly, craniofacial abnormalities, hand or foot malformation, and hirsutism in the face. Prenatally, CDLS has some distinctive features in ultrasound, such as fetal growth retardation, craniofacial abnormalities, and limb malformation. CDLS has a broad spectrum of clinical presentation; its prognosis may vary based on the abnormality and the symptoms caused.

Open article ↗



2026-05-09 | Cohesin variants associated with human reproductive and developmental disorders.

The cohesin complex is an evolutionarily conserved multi-subunit protein assembly essential for sister chromatid cohesion, meiotic recombination, DNA double-strand break repair, and transcriptional regulation. Pathogenic variants in its subunits are implicated in a spectrum of reproductive and developmental disorders, including non-obstructive azoospermia, premature ovarian insufficiency, reproductive aging, aneuploidy, Cornelia de Lange syndrome, Roberts syndrome, cancer, and neuro-psychiatric disease. Consequently, identifying cohesin mutations is a priority for precision diagnostics and personalized medicine. This review systematically summarizes the cohesin variants linked to these pathologies, exploring their molecular mechanisms and clinical manifestations. A deeper understanding of these variants is crucial not only for deciphering disease etiology but also for guiding the development of targeted diagnostic strategies and therapeutic interventions, ultimately improving patient management and outcomes.

Open article ↗



2026-03-17 | Clinical and molecular findings in Cornelia de Lange syndrome. Case series.

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder caused by pathogenic variants in genes related to the regulation of cohesin transcription. It presents a very heterogeneous clinical phenotype, with wide variability in severity. To describe the clinical and molecular findings in patients diagnosed with CdLS. Observational and descriptive study conducted in patients with CdLS evaluated between April 1, 2020, and April 1, 2024, at the Clinical Genetics Unit, Pediatrics Service, of the Hospital Regional de Antofagasta. The diagnostic algorithm suggested by the first international consensus statement for CdLS was used, and the results of the genetic studies were analyzed. Six patients aged 0-17 years were included; 4 were male. Global developmental delay and/or intellectual disability, the presence of synophrys, abnormalities of the nose and lips, and hypertrichosis were confirmed in all patients. Heterozygous variants in the NIPBL gene were found in 5/6 patients (83.33%), all classified as pathogenic and associated with cases of classic CdLS. Four of the variants described in this study have not been previously reported in the literature. Neurological alterations, facial dysmorphism, and hypertrichosis were present in all patients studied. Heterozygous pathogenic variants in the NIPBL gene represented the main etio- pathogenic cause, allowing for timely family genetic counseling.

Open article ↗



2026-01-09 | Whole Exome Sequencing Uncovers Genetic Syndromes Associated with Orofacial Clefts presenting with Limb abnormalities in a Sub-Saharan African cohort.

Orofacial clefts (OFCs) are the most frequent congenital craniofacial anomalies that occur during embryonic development. The incidence is ~1 in 700 live births; it may occur in isolation or with other abnormalities, such as limb deformities. Congenital limb malformations are the second most prevalent birth defect, affecting 1 per 500 to 1000 live births. It can also occur in isolation or as part of a syndrome. This study investigated the genetic aetiology of OFCs co-occurring with limb abnormalities in a Sub-Saharan African cohort. Nine unrelated probands with concurrent OFC and limb anomalies were recruited, including one multiplex family involving an affected mother and proband. Whole exome sequencing (WES) was performed at 100X on the DNA samples obtained from affected families, utilising paired-end configuration on the Illumina HiSeq platform. Variant calling utilized the Sentieon workflow. Rare, deleterious variants were identified in accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines on variant classification. De novo and other variants predicted as pathogenic were prioritized based on all possible Mendelian inheritance patterns, including variable penetrance and expressivity. Pathway enrichment analysis, protein-protein interactions, and gene expression analysis were undertaken to decipher the biological functions of implicated genes. All cases were syndromic, presenting with preaxial and postaxial limb anomalies along with other craniofacial features. WES revealed plausible pathogenic variants in pleiotropic genes (TP63, NIPBL, MYH3, FGFR2) in four simplex cases. In four other simplex probands, multiple rare variants were identified in developmentally relevant genes (e.g., RGPD5, FAM90A26, FOXD4L1, FAM170A, DLG1, ANKRD1, TRIM74, TRIM73, PRDM9) necessary for normal craniofacial and limb development. The multiplex family had two affected individuals (the mother and the proband), both carrying a TP63 variant, consistent with autosomal dominant inheritance with variable expressivity. Most of the observed variants were de novo, with some being novel. While some cases can be attributed to single-gene syndromes (e.g., NIPBL-associated Cornelia de Lange Syndrome), others may result from multiple co-occurring syndromes. These findings will inform recurrence risk estimates, genetic counselling, and clinical management.

Open article ↗



2025-12-15 | A Review on Cornelia De Lange Syndrome

Cornelia de Lange Syndrome (CdLS) is a rare genetic condition that affects multiple body systems. It is marked by distinctive facial features, delayed growth, limb differences, and a wide range of cognitive and behavioral challenges. First identified in 1933 by Dutch pediatrician Cornelia de Lange, the syndrome occurs in roughly 1 in 10,000 to 30,000 live births. The severity of CdLS varies widely, from classic, clearly recognizable cases to milder or atypical forms with subtler features. The disorder is mainly caused by mutations in genes related to the cohesin complex—such as NIPBL, SMC1A, SMC3, RAD21, HDAC8, BRD4, ANKRD11, and MAU2—which disrupt gene regulation, DNA repair, and oxidative stress responses, though basic sister chromatid cohesion is usually intact. Individuals with CdLS may display a combination of facial and limb abnormalities, growth restriction, intellectual disability, behavioral difficulties, and problems involving organs such as the heart, digestive system, kidneys, eyes, and reproductive organs. Mosaicism is relatively common and can influence the severity and variability of symptoms, sometimes making diagnosis more challenging. Genetic testing through targeted gene panels or exome sequencing is key for diagnosis, with careful selection of tissue samples to detect mosaic variants. Prenatal diagnosis is possible in families at risk or when ultrasound findings raise suspicion, but interpretation can be complex. Managing CdLS requires a multidisciplinary approach, including nutritional support, surgical interventions, medications for seizures or behavioral concerns, and ongoing therapies such as physical, occupational, and speech therapy. Despite advances in genomic research, some cases remain unexplained, underscoring the complexity of this condition.

Open article ↗



oligonucleotides
2023-04-01 | Genetic and Genomic Analyses of Drosophila melanogaster Models of Chromatin Modification Disorders.

Switch/Sucrose Non-Fermentable (SWI/SNF)-related intellectual disability disorders (SSRIDDs) and Cornelia de Lange syndrome are rare syndromic neurodevelopmental disorders with overlapping clinical phenotypes. SSRIDDs are associated with the BAF (Brahma-Related Gene-1 Associated Factor) complex, whereas CdLS is a disorder of chromatin modification associated with the cohesin complex. Here, we used RNA interference in Drosophila melanogaster to reduce expression of six genes (brm, osa, Snr1, SMC1, SMC3, vtd) orthologous to human genes associated with SSRIDDs and CdLS. These fly models exhibit changes in sleep, activity, startle behavior (a proxy for sensorimotor integration) and brain morphology. Whole genome RNA sequencing identified 9,657 differentially expressed genes (FDR < 0.05), 156 of which are differentially expressed in both sexes in SSRIDD- and CdLS-specific analyses, including Bap60, which is orthologous to SMARCD1, a SSRIDD-associated BAF component, k-means clustering reveals genes co-regulated within and across SSRIDD and CdLS fly models. RNAi-mediated reduction of expression of six genes co-regulated with focal genes brm, osa, and/or Snr1 recapitulated changes in behavior of the focal genes. Based on the assumption that fundamental biological processes are evolutionarily conserved, Drosophila models can be used to understand underlying molecular effects of variants in chromatin-modification pathways and may aid in discovery of drugs that ameliorate deleterious phenotypic effects.

Open article ↗



2021-06-08 | Neuropsychiatric Functioning in CDLS: A Detailed Phenotype and Genotype Correlation

Abstract Background : Cornelia de Lange Syndrome (CdLS) is a rare genetic disorder and its phenotype clinical expression is widely variable. Despite the growing interest on genotype-phenotype correlations and on behaviour phenotype of genetic syndromes, specific studies in CdLS cohorts evaluating the correlations between genotype and neurodevelopmental characteristics, Behaviour and communicative aspects are limited, most of these studies are descriptive and there is a lack of specific assessment protocols. Methods : Neurodevelopmental and Behavioural phenotype of all the patients (N = 38) was assessed using a specific neuropsychiatric protocol, concerning Intellectual Quotient (IQ), General Quotient of Development (GQ), communicative skills, behavioural aspects and adaptive behaviour based on direct and indirect evaluation. Subsequently, we searched for possible genotype–phenotype correlations comparing individuals with NIPBL variants (CdLS NIPBL mutated group) and patients with negative molecular results (CdLS clinical diagnosis group). Results : The first part of the study showed a higher percentage of subjects with normal Intellectual Quotient (IQ) and Borderline Intellectual Functioning if compared with previous data; adaptive skills were lower than expected for age in all participants and the weakest areas were Socialization, Motor Skills, and Communication. Expressive language was more compromised than receptive language, nevertheless receptive abilities were also impaired. 39.5% of the sample presented with Autism Spectrum Disorder (ASD). By stratifying CdLS phenotypes by genetic, NIPBL mutated individuals demonstrated a worse trend in cognitive functioning, in communication expressive skills, in motor skills and in ASD symptoms in comparison with the Clinical Diagnosis Group. Individuals with non-Truncating mutation (mostly missense) displayed better abilities in Communication and in relational aspects with no ASD while Truncating individuals presented with worse abilities in Daily Living Skills, Socialization, Motor Skills, and Communicative abilities. Conclusions : These findings should increase our awareness of the strengths and weaknesses points in CdLS individuals to guide appropriate targeted management; interventions addressing communicative impairments represent a clinical priority in CdLS patients.

Open article ↗



2017-12-20 | Regulation of the cohesin-loading factor NIPBL: Role of the lncRNA NIPBL-AS1 and identification of a distal enhancer element

Cohesin is crucial for genome stability, cell division, transcription and chromatin organization. Its functions critically depend on NIPBL, the cohesin-loader protein that is found to be mutated in >60% of the cases of Cornelia de Lange syndrome (CdLS). Other mutations are described in the cohesin subunits SMC1A, RAD21, SMC3 and the HDAC8 protein. In 25–30% of CdLS cases no mutation in the known CdLS genes is detected. Until now, functional elements in the noncoding genome were not characterized in the molecular etiology of CdLS and therefore are excluded from mutation screening, although the impact of such mutations has now been recognized for a wide range of diseases. We have identified different elements of the noncoding genome involved in regulation of the NIPBL gene. NIPBL-AS1 is a long non-coding RNA transcribed upstream and antisense to NIPBL. By knockdown and transcription blocking experiments, we could show that not the NIPBL-AS1 gene product, but its actual transcription is important to regulate NIPBL expression levels. This reveals a possibility to boost the transcriptional activity of the NIPBL gene by interfering with the NIPBL-AS1 lncRNA. Further, we have identified a novel distal enhancer regulating both NIPBL and NIPBL-AS1. Deletion of the enhancer using CRISPR genome editing in HEK293T cells reduces expression of NIPBL, NIPBL-AS1 as well as genes found to be dysregulated in CdLS.

Open article ↗



2017-09-12 | Decreased cohesin in the brain leads to defective synapse development and anxiety-related behavior.

Abnormal epigenetic regulation can cause the nervous system to develop abnormally. Here, we sought to understand the mechanism by which this occurs by investigating the protein complex cohesin, which is considered to regulate gene expression and, when defective, is associated with higher-level brain dysfunction and the developmental disorder Cornelia de Lange syndrome (CdLS). We generated conditional Smc3-knockout mice and observed greater dendritic complexity and larger numbers of immature synapses in the cerebral cortex of Smc3+/- mice. Smc3+/- mice also exhibited more anxiety-related behavior, which is a symptom of CdLS. Further, a gene ontology analysis after RNA-sequencing suggested the enrichment of immune processes, particularly the response to interferons, in the Smc3+/- mice. Indeed, fewer synapses formed in their cortical neurons, and this phenotype was rescued by STAT1 knockdown. Thus, low levels of cohesin expression in the developing brain lead to changes in gene expression that in turn lead to a specific and abnormal neuronal and behavioral phenotype.

Open article ↗



2015-11-25 | Esco2 regulates cx43 expression during skeletal regeneration in the zebrafish fin.

Background: Roberts syndrome (RBS) is a rare genetic disorder characterized by craniofacial abnormalities, limb malformation, and often severe mental retardation. RBS arises from mutations in ESCO2 that encodes an acetyltransferase and modifies the cohesin subunit SMC3. Mutations in SCC2/NIPBL (encodes a cohesin loader), SMC3 or other cohesin genes ( SMC1, RAD21/MCD1 ) give rise to a related developmental malady termed Cornelia de Lange syndrome (CdLS). RBS and CdLS exhibit overlapping phenotypes, but RBS is thought to arise through mitotic failure and limited progenitor cell proliferation while CdLS arises through transcriptional dysregulation. Here, we use the zebrafish regenerating fin model to test the mechanism through which RBS‐type phenotypes arise. Results : esco2 is up‐regulated during fin regeneration and specifically within the blastema. esco2 knockdown adversely affects both tissue and bone growth in regenerating fins—consistent with a role in skeletal morphogenesis. esco2 ‐knockdown significantly diminishes cx43/gja1 expression which encodes the gap junction connexin subunit required for cell–cell communication. cx43 mutations cause the short fin ( sof b123 ) phenotype in zebrafish and oculodentodigital dysplasia (ODDD) in humans. Importantly, miR‐133‐dependent cx43 overexpression rescues esco2 ‐dependent growth defects. Conclusions : These results conceptually link ODDD to cohesinopathies and provide evidence that ESCO2 may play a transcriptional role critical for human development. Developmental Dynamics 245:7–21, 2016 . © 2015 Wiley Periodicals, Inc.

Open article ↗



other
2026-05-13 | Idiopathic retinal vasculitis with neovascularisation in Cornelia de Lange syndrome associated with a novel HDAC8 variant.

To describe a case of unilateral idiopathic retinal vasculitis with neovascularisation in a patient with Cornelia de Lange syndrome (CdLS) and to expand the known ophthalmic phenotype of this condition. Observational case report of an 18-year-old girl with clinically diagnosed CdLS associated with a novel HDAC8 variant. Multimodal retinal imaging, including fundus photography, fluorescein angiography, and optical coherence tomography, was performed. Infectious and autoimmune causes were systematically investigated and excluded. The patient developed unilateral retinal vasculitis with macular edema and neovascularisation. Imaging confirmed vascular leakage, retinal ischemia, and macular involvement in the affected eye. Treatment with intravitreal aflibercept and panretinal photocoagulation led to regression of neovascularisation; however, recurrent macular edema was observed during follow-up. This case represents the first report of inflammatory retinal disease in CdLS. It broadens the spectrum of ocular manifestations associated with the disorder and emphasizes the importance of early and thorough retinal assessment in these patients.

Open article ↗



2025-04-25 | Recurrent Sinopulmonary Infections in an 8-Year-Old Boy with Cornelia de Lange Syndrome

Introduction Cornelia de Lange syndrome (CdLS) is a rare genetic disorder with an estimated prevalence of 1 in 10,000 live births worldwide. It presents with a spectrum of severity, ranging from mild to severe marked by characteristic facial features, growth delay, intellectual disability, heart defects, gastrointestinal issues, hearing loss, myopia, and frequent upper and lower respiratory infections. The majority of genetic variants found in CdLS are associated with variants in the NIPBL gene, which encodes a regulatory protein crucial for the function of the cohesin complex. Case Description We present an 8-year-old male with a history of dysmorphic facial features, global developmental delay, aortic coarctation, lagophthalmos, hearing loss, and recurrent upper and lower sinopulmonary infections. There is no family history of immunodeficiencies or other genetic syndromes and patients born outside the United States. Commercial whole-exome sequencing performed at 7 years of age revealed a heterozygous de novo pathogenic variant in NIPBL (c.8257 C&gt;G, p.R2753G). Complete blood count with differential, basic lymphocyte subsets, and immunoglobulins were within normal limits. Patient was immune to varicella, hepatitis B, tetanus, and diphtheria post-vaccination but only had 1/23 strep pneumoniae titers above 1.3 ug/mL and only 4/23 above 0.5 ug/mL after primary Prevnar 13 series. Advanced phenotyping showed increased percentage of transitional B cells, increased proportion of CD8+ TEMRA cells, reverse CD4/CD8 ratio at 0.69, and normal mitogen-induced lymphocyte proliferation to PHA and ConA with PWM at 50% below the lower limit of normal. Patient given booster vaccination with Pneumovax and had improvement in strep pneumoniae titers to 16/23 protective above 1.3 ug/mL and decreased clinical infections. Discussion The cohesin protein complex plays a significant role in the immune system, and altered expression of immune-related genes in patients with CdLS may explain the varying degrees of immunodeficiency observed in these individuals. Although no specific immune defect has been universally identified in CdLS, and there are no established guidelines for managing immune issues or vaccination in this population, it is important to conduct clinical immunologic evaluations for CdLS patients who experience recurrent infections as booster vaccinations can significantly improve these patients’ quality of life.

Open article ↗



2023-11-02 | Coats' Disease in a Patient With Cornelia de Lange Syndrome: Management With Laser and Bevacizumab.

Cornelia de Lange syndrome is a congenital disorder with multisystem abnormalities including multiple ocular findings. The authors report a case of Coats' disease in a patient with Cornelia de Lange syndrome who was successfully treated with laser and intravitreal bevacizumab. This case demonstrates the importance of fluorescein angiography in making the diagnosis and directing treatment and the efficacy of combined laser with intravitreal anti-vascular endothelial growth factor therapy for persistent vascular leakage associated with Coats' disease in Cornelia de Lange syndrome. [J Pediatr Ophthalmol Strabismus. 2023;60(4):e45-e48.].

Open article ↗



2020-04-19 | Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange syndrome, and prosecution during the COVID-19 pandemic.

Psychomotor delay and intellectual disability are potential limitations in psoriasis management, due to low compliance, and strict dependence from caregivers intervention. We report our successful experience with a 58-year-old woman, who was genetically affected by Cornelia De Lange syndrome, which causes intellectual disability and psychomotor disorders. The patient had been already treated with topical and traditional therapies, without any clinical benefits. Eventually, she adhered to guselkumab treatment. The compliance was excellent, significant improvements were observed after only 3 months of treatment, without adverse effects. During follow-up, the COVID-19 pandemic address concern on the possible increased risk of infection due to immunosuppression. In agreement with current Italian recommendations, risk and benefits profile was discussed with the patient's legal tutor and the decision to continue the treatment was taken. Psoriasis complete clarification was maintained during the most difficult period of the Italian outbreak, allowing the patient to remain safely at home.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.